Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

a study on Mucopolysaccharidosis Sanfilippo Syndrome

Summary

Eligibility
for people ages 12 months to 18 years (full criteria)
Location
at Oakland 5378538, California 5332921 and other locations
Dates
study started
study ends around
Principal Investigator
by Paul Harmatz, MD

Description

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

Official Title

A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Keywords

Sanfilippo Syndrome Type A, Mucopolysaccharidosis Type III Subtype A, MPS IIIA, Mucopolysaccharidosis III

Eligibility

You can join if…

Open to people ages 12 months to 18 years

  • Participants with documented MPS IIIA diagnosis
  • Participants aged ≥ 12 months and ≤ 18 years

You CAN'T join if...

  • Participants with significant non-MPS IIIA related central nervous system impairment
  • Participants with previous complication from intraventricular drug administration
  • Participants with contraindications for MRI scans and for neurosurgery
  • Participants that received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study
  • Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy

Locations

  • UCSF Benioff Children's Hospital accepting new patients
    Oakland 5378538 California 5332921 94609 United States
  • University of Minnesota accepting new patients
    Minneapolis 5037649 Minnesota 5037779 55455 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
GC Biopharma Corp
ID
NCT06567769
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 9 study participants
Last Updated